CD14 and neoplasm: Both their ability to impair anti-tumor immune responses and that they may be a promising therapeutic target make a compelling case for the development of standardized tools and/or assays to measure CD14+HLA-DRlo/neg monocytes in a manner that is useful for guiding therapeutic decisions for patients receiving immunotherapy.